The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 9×
“Increasing mitochondrial ROS (mROS) has also been investigated to sensitize cells to RT. Post-radiation, the Hypoxia Inducible Factor 1α (HIF1α) target gene pyruvate dehydrogenase kinase (PDK) has been shown to be upregulated.”
BackgroundInfluentialSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Next, earlier studies have shown that TMZ is a direct cause of hypermutation in recurrent gliomas as seen by the accumulation of a TMZ-specific mutational signature in these tumors [39,62].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668 · cited 1×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ‐in‐ duced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 2×
“TAMs are the dominant infiltrating immune population in glioma constituting around 30–40% of the total tumor volume [25,132,138].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“The GBM TME attracts TAMs to the tumor and polarizes them to an anti-inflammatory or pro-tumorigenic ‘M2′-like state, thus current studies are aimed at inhibiting their recruitment or survival in the TME, allowing for their functional re-education to an anti-tumor ‘M1′-like state, or targeting the tumor using monoclon…”
BackgroundMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048 · cited 1×
“Cancers with MMR deficiencies have been approved to be treated clinically by the PD‐1 blocker pembrolizumab [63,64].”
BackgroundAn Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873 · cited 1×
“Further, lineage tracing of uniquely barcoded single cells in vivo has shown that these cells exhibit plasticity, and a single cell type has the potential to convert into all other cell types influenced by the in vivo TME, collectively contributing to the heterogeneity in GBM and rendering GBM ther‐ apeutically resist…”
BackgroundLee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995 · cited 1×
“Based on Inter-tumor heterogeneity studies of bulk gene expression analysis from TCGA, glioblastoma (GBM) has been classified into the Proneural (PN), Classical (CL) and Mesenchymal (MES) tumor subtypes [33,34].”
Self-citationAnalysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737 · cited 1×
“Further, lineage tracing of uniquely barcoded single cells in vivo has shown that these cells exhibit plasticity, and a single cell type has the potential to convert into all other cell types influenced by the in vivo TME, collectively contributing to the heterogeneity in GBM and rendering GBM ther‐ apeutically resist…”
BackgroundKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501 · cited 1×
“However, clinical trials using anti-PD-1 therapy in GBM have shown limited success [14].”
BackgroundSpliced segments at the 5′ terminus of adenovirus 2 late mRNA
Berget, S. M., Moore, C., & Sharp, P. A. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.8.3171 · Cited by 1,413 · cited 1×
“AS is the process of removing introns and joining together exons [66] in ways that are dictated by the spliceo‐ some and many accompanying splicing factors [67,68].”
BackgroundElectrical and synaptic integration of glioma into neural circuits
Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., Tam, L. T., Espenel, C., Ponnuswami, A., Ni, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1563-y · Cited by 1,366
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362 · cited 3×
“Next, earlier studies have shown that TMZ is a direct cause of hypermutation in recurrent gliomas as seen by the accumulation of a TMZ-specific mutational signature in these tumors [39,62].”
BackgroundAlternative splicing as a regulator of development and tissue identity
Baralle, F. E., & Giudice, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.27 · Cited by 1,333 · cited 1×
“AS is the process of removing introns and joining together exons [66] in ways that are dictated by the spliceo‐ some and many accompanying splicing factors [67,68].”
BackgroundShort-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172 · cited 1×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ‐in‐ duced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundTemozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,163 · cited 1×
“Tumors expressing MGMT are intrinsically resistant to TMZ, however others be‐ come resistant post TMZ treatment as chromatin changes can allow MGMT to become expressed [103].”
BackgroundJacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149 · cited 1×
“These organoid tumor models also recapitulate other features of GBM tumors which are difficult to model in in vitro conditions such as hypoxic gradients and tumor heterogeneity [57,58].”
BackgroundWeller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134 · cited 1×
“The clinical trial targeting EGFRvIII, a constitu‐ tively active mutant of EGFR, through the vaccine rindopepimut (phase III ACT IV clinical trial) did not show any improvement in patient survival in GBM, possibly due to the loss of EGFRvIII expression upon therapy or in recurrent GBM [46].”
BackgroundA day in the life of the spliceosome
Matera, A. G., & Wang, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3742 · Cited by 1,074 · cited 1×
“complex made up of multiple small nuclear RNA (snRNAs)–U1, U2, U4, U5 and U6–that combine with over 80 proteins to create RNA‐protein complexes known as small nuclear ribonucleoproteins (snRNPs, pronounced “snurps”) [69,70].”
BackgroundChallenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959 · cited 1×
“Standard care involves surgical resection followed by radiotherapy along with concomitant chemotherapy with temozolomide (TMZ) and adjuvant doses of TMZ [2,3].”
BackgroundVitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
DNA Base Damage by Reactive Oxygen Species, Oxidizing Agents, and UV Radiation
Cadet, J., & Wagner, J. R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012559 · Cited by 903 · cited 1×
“The conventional mechanism of action for radiation is dependent on reactive oxygen species (ROS) that cause DNA damage resulting in oxidative stress [89].”
BackgroundImmune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889 · cited 1×
“Moreover, even combination therapies coupling anti‐ PD‐1/PDL‐1 with other targets which have proven to be successful pre‐clinically have not progressed ahead to clinical trials [44,45].”
BackgroundTemozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885 · cited 8×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ-induced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundInfluentialBouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857 · cited 2×
“However, another study has shown clinical benefit in a pair of siblings with recurrent GBM having biallelic mismatch repair deficiency, wherein treatment with the PD-1 inhibitor nivolumab showed significant clinical and radiological responses [12].”
BackgroundResultLindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765 · cited 1×
“Hypoxia, or lack of oxygen, is a common feature of fast-growing tumors like GBM as they quickly outgrow their vasculature and subsequent nutrient supply [113].”
BackgroundMechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751 · cited 6×
“Thus, the clinical response to anti‐PD‐1 treatment in GBM is associated with specific mo‐ lecular patterns and clonal evolution during treatment, lack of which develops an ac‐ quired resistant state in the glioma tumor, thus resulting in therapy failure [24,147].”
BackgroundInfluentialRoles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731 · cited 1×
“Nevertheless, multiple clinical trials have been designed to answer this question [80].”
BackgroundMetabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 720 · cited 1×
“Furthermore, it has been shown that a PDK inhibitor, dichloroacetate (DCA), can cross the blood brain barrier (BBB) and was well tolerated in patients [101].”
BackgroundClonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720 · cited 6×
“Also, most of the hypermutated tumors gain mutations in genes encoding DNA mismatch repair (MMR) proteins, and primarily MutS homolog 2 (MSH2) and MutS homolog 6 (MSH6) [41].”
BackgroundInfluentialPatient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012) · Glia · doi:10.1002/glia.21264 · Cited by 712
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677 · cited 10×
“, 2020 which studied the mutational burden by pro‐ filing 10,294 gliomas, found that hypermutant tumors or tumors with high mutation bur‐ den have a worse overall survival as compared to non‐hypermutant tumors in different types of glioma including 1p/19q co‐deleted oligodendrogliomas, isocitrate dehydrogen‐ ase 1/2 (…”
BackgroundResultInfluentialCellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., Rasmussen, R., Dwivedi, B., Seby, S., Wolf, S. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2310 · Cited by 675 · cited 1×
“In GEMMs of platelet derived growth factor subunit B (PDGFB)-driven glioma, it has been shown that TAMs derived from bone marrow-derived monocytes constitute the major proportion (up to 85%) of TAMs in the GBM TME, whereas those derived from brain-resident microglia constitute only 15% of the total TAM population in G…”
MethodHubert, C. G., Rivera, M., Spangler, L. C., Wu, Q., Mack, S. C., Prager, B. C., Couce, M., McLendon, R. E., Sloan, A. E., & Rich, J. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2402 · Cited by 663
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662 · cited 1×
“Standard care involves surgical resection followed by radiotherapy along with concomitant chemotherapy with temozolomide (TMZ) and adjuvant doses of TMZ [2,3].”
BackgroundKim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658 · cited 1×
“c-Myc interacting with HIF1α increases the expression of the glucose transporter GLUT1, which allows for an influx of glucose, and hexokinase 2 (HK2), the enzyme necessary for the first step of glycolysis, thereby directing the cells towards glycolysis [120].”
BackgroundMüller, S., Kohanbash, G., Liu, S. J., Alvarado, B., Carrera, D., Bhaduri, A., Watchmaker, P. B., Yagnik, G., Di Lullo, E., Malatesta, M., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1362-4 · Cited by 654 · cited 1×
“Furthermore, a scRNA seq study showed that blood-derived TAMs up-regulate immunosuppressive cytokines, exhibit altered metabolism as compared to microglia-derived TAMs, and that the gene-signature of blood-derived TAMs correlates with an inferior survival in patients with glioma [142].”
BackgroundButowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576 · cited 1×
“Moreover, even combination therapies coupling anti‐ PD‐1/PDL‐1 with other targets which have proven to be successful pre‐clinically have not progressed ahead to clinical trials [44,45].”
BackgroundSynaptic proximity enables NMDAR signalling to promote brain metastasis
Zeng, Q., Michael, I. P., Zhang, P., Saghafinia, S., Knott, G., Jiao, W., McCabe, B. D., Galván, J. A., Robinson, H. P. C., Zlobec, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1576-6 · Cited by 574 · cited 1×
“Further it is shown that such neural-glial signaling is involved in breast-to-brain metastasis through N-methylD-aspartate (NMDA) receptor mediated neuronal signaling [150].”
BackgroundIshii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
Therapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 561 · cited 1×
“Many drugs have now been designed to specifically target SF3B1, including in glioma [76,77].”
BackgroundLongitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 561 · cited 2×
“The driver muta‐ tions manifested in the original tumor were retained at recurrence with a slim possibility of developing or acquiring new mutations at recurrence and the rate of hypermutation was different across different glioma subtypes [11].”
BackgroundStem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524 · cited 1×
“niche comprising of endothelial cells, pericytes and vascular smooth muscle cells, astro‐ cytes, and fibroblasts all of which interact with and drive the proliferation of the tumor neoplastic population [25,26].”
BackgroundSelf-citationControl of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517 · cited 1×
“The expression of AHR is the highest in GBM-relative to lower grade gliomas and is independently correlated with poor patient prognosis, thus making AHR an attractive target for GBM immunotherapy [144].”
BackgroundMirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509 · cited 1×
“Radiation therapy (RT) and temozolomide (TMZ) treatment have been the two main workhorses in treating GBM [87].”
BackgroundPI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)
Xie, Y., Shi, X., Sheng, K., Han, G., Li, W., Zhao, Q., Jiang, B., Feng, J., Li, J., & Gu, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9713 · Cited by 505
Modeling Patient-Derived Glioblastoma with Cerebral Organoids
Linkous, A., Balamatsias, D., Snuderl, M., Edwards, L., Miyaguchi, K., Milner, T., Reich, B., Cohen-Gould, L., Storaska, A., Nakayama, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.063 · Cited by 502 · cited 2×
“GSCs home towards human embryonic stem cell (hESC)‐derived cerebral organoids and deeply invade and proliferate within the host tissue to form tumors that phenocopy hu‐ man tumors in clinic [55].”
BackgroundMa, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486 · cited 3×
“For ex‐ ample, monoclonal antibodies targeting programmed cell death protein 1 (PD‐1) protein and its ligand programmed death‐ligand (PDL‐1) to enhance the cytotoxic activity of CD8+ T cells has been found to be successful in other cancers such as melanoma and non‐small cell lung cancer but failed to show success in G…”
BackgroundInfluentialCahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 452 · cited 1×
“The association of MMR mutations and hypermutation in glioma has been studied for a long time [60,61], however, they have”
BackgroundSchoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443 · cited 1×
“With this knowledge, experiments have been focused on manipulating the levels of glutathione and ascorbic acid to treat radioresistant tumors [92].”
BackgroundHunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 434 · cited 1×
“The association of MMR mutations and hypermutation in glioma has been studied for a long time [60,61], however, they have”
BackgroundImmune Microenvironment in Glioblastoma Subtypes
Chen, Z., & Hambardzumyan, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01004 · Cited by 432 · cited 1×
“These checkpoint inhibitors are expressed by T cells and perform inhibitory functions by interacting with their corresponding ligands that are expressed on both the tumor and TAMs, to release cytokines, leading to inhibition of T cell function, polarization of macrophages to a pro-tumorigenic state and thus tumor prog…”
BackgroundKim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411 · cited 1×
“rence are not present in the primary tumor [39,41,42].”
BackgroundIntratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
Qazi, M. A., Vora, P., Venugopal, C., Sidhu, S. S., Moffat, J., Swanton, C., & Singh, S. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx169 · Cited by 408 · cited 6×
“The therapy-resistant clones then seed the recurrent tumor which is comprised of a new heterogenous TME having a distinct clonal population from the original tumor and harbors a distinct set of genetic mutations which are both new and common to the initial tumor [38].”
BackgroundInfluentialMetabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis
Daye, D., & Wellen, K. E. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.002 · Cited by 374 · cited 4×
“As (R)2-hydroxyglutarate (HG), the metabolite made by IDHmut, inhibits the 2-oxoglutarate-dependent transaminases branched chain amino acid transaminase (BCAT)-1 and BCAT-2, these cells become dependent on GLS for glutamate and subsequent GSH production [98].”
BackgroundInfluentialMcBrayer, S. K., Mayers, J. R., DiNatale, G. J., Shi, D. D., Khanal, J., Chakraborty, A. A., Sarosiek, K. A., Briggs, K. J., Robbins, A. K., Sewastianik, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.038 · Cited by 368 · cited 4×
“Glutaminase (GLS) catalyzes the hydrolysis of glutamine to glutamate (and ammonia), which is one of the three amino acids necessary to make the antioxidant GSH [97].”
BackgroundInfluentialThe Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation
Wang, L., Babikir, H., Müller, S., Yagnik, G., Shamardani, K., Catalan, F., Kohanbash, G., Alvarado, B., Di Lullo, E., Kriegstein, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0329 · Cited by 363 · cited 1×
“population [138,139] which has been associated with a poor prognosis in GBM [140].”
BackgroundPavlyukov, M. S., Yu, H., Bastola, S., Minata, M., Shender, V. O., Lee, Y., Zhang, S., Wang, J., Komarova, S., Wang, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.012 · Cited by 320 · cited 1×
“Following this trend, post TMZ treatment, RBM11 was shown to increase in expression where it was then packaged into apoptotic vesicles that were taken up by surrounding surviving cells, which changed overall splicing patterns and decreased TMZ drug sensitivity [83].”
BackgroundMechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer
Du, J., Martin, S. M., Levine, M., Wagner, B. A., Buettner, G. R., Wang, S.-H., Taghiyev, A. F., Du, C., Knudson, C. M., & Cullen, J. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1713 · Cited by 316
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316 · cited 1×
“Nevertheless, combination therapy using an MGMT inhibitor, O6-benzylguanine (O6BG) alongside TMZ did not show any clinical benefit compared to TMZ alone [9,10].”
BackgroundReprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Zannella, V. E., Dal Pra, A., Muaddi, H., McKee, T. D., Stapleton, S., Sykes, J., Glicksman, R., Chaib, S., Zamiara, P., Milosevic, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1787 · Cited by 314
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors
Rampling, R., Cruickshank, G., Lewis, A. D., Fitzsimmons, S. A., & Workman, P. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90432-4 · Cited by 304 · cited 1×
“Normal brain oxygenation was shown to be ~40 mmHg by Eppendorf needle electrode, whereas GBM clocked in at ~10 mmHg where 0-10 mmHg was shown to correlate with RT resistance [114,115].”
MethodThe powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280 · cited 1×
“ASOs can be used to target certain splicing factors, as well as tumor-specific splicing events [153].”
BackgroundAnalysis of the Effects of Oxygen Supply and Demand on Hypoxic Fraction in Tumors
Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F., & Dewhirst, M. W. (1995) · Acta Oncologica · doi:10.3109/02841869509093981 · Cited by 276 · cited 1×
“Inhibition of the electron transport chain (ETC) at the mitochondrial membrane, which requires oxygen in the final step, allows for an increase in tumor oxygen concentrations and re-sensitization to radiation [125].”
BackgroundA novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J.-H., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 273 · cited 1×
“even MGMT hypermethylated glioma cells show robust expression of MGMT through promoter‐independent mechanisms, thereby developing resistance to TMZ treatment [7,8].”
BackgroundWang, Y., Lin, Y.-X., Qiao, S.-L., An, H.-W., Ma, Y., Qiao, Z.-Y., Rajapaksha, R. P. Y. J., & Wang, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 266
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
Ashton, T. M., Fokas, E., Kunz-Schughart, L. A., Folkes, L. K., Anbalagan, S., Huether, M., Kelly, C. J., Pirovano, G., Buffa, F. M., Hammond, E. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12308 · Cited by 247
von Roemeling, C. A., Wang, Y., Qie, Y., Yuan, H., Zhao, H., Liu, X., Yang, Z., Yang, M., Deng, W., Bruno, K. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15129-8 · Cited by 242 · cited 1×
“Combination of chemotherapy with immune modulators, like TMZ with PD-1 blockade and CD47, and others could be an interesting avenue to study in the future [152].”
BackgroundEmerging roles of Myc in stem cell biology and novel tumor therapies
Yoshida, G. J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0835-y · Cited by 241 · cited 1×
“This switch to glycolysis has been shown to help cancer cells adapt to hypoxic conditions by increasing the synthesis of ATP and biomolecules [121].”
BackgroundPurine metabolism regulates DNA repair and therapy resistance in glioblastoma
Zhou, W., Yao, Y., Scott, A. J., Wilder-Romans, K., Dresser, J. J., Werner, C. K., Sun, H., Pratt, D., Sajjakulnukit, P., Zhao, S. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17512-x · Cited by 240 · cited 1×
“double‐strand breaks (DSBs), and thus inhibiting these metabolites alleviates resistance to RT in GBM [16].”
BackgroundTargeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238 · cited 1×
“Reoxygenation via hyperbaric chambers [123] or misonidazole and nimorazole–oxygen mimetics–have been moderately successful in increasing radiation sensitivity [124].”
BackgroundVaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227 · cited 1×
“Patient‐derived xenograft (PDX) models on the other hand provide a complete mutational profile that can be stably passed in vivo, pos‐ sess a TME that can form heterogenous cells and are thought to recapitulate the histo‐ pathological features of the parent GBM [52].”
BackgroundThe Cancer Spliceome: Reprograming of Alternative Splicing in Cancer
El Marabti, E., & Younis, I. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00080 · Cited by 220 · cited 1×
“Accumulated studies have shown that splicing factors are dynamically expressed be‐ tween normal brain and gliomas [81].”
BackgroundHadoux, J., Favier, J., Scoazec, J., Leboulleux, S., Al Ghuzlan, A., Caramella, C., Déandreis, D., Borget, I., Loriot, C., Chougnet, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28913 · Cited by 210
Oxidative phosphorylation as a potential therapeutic target for cancer therapy
Sica, V., Bravo‐San Pedro, J. M., Stoll, G., & Kroemer, G. (2020) · International Journal of Cancer · doi:10.1002/ijc.32616 · Cited by 209 · cited 1×
“Inhibitors to complex I (biguanides), complex II (alphatocopheryl, lonidamine, and VLX600), complex III (atovaquone), and complex IV (VLX600 and arsenic trioxide) have been tested [126].”
BackgroundBraun, C. J., Stanciu, M., Boutz, P. L., Patterson, J. C., Calligaris, D., Higuchi, F., Neupane, R., Fenoglio, S., Cahill, D. P., Wakimoto, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.018 · Cited by 208 · cited 2×
“They went on to show that PRMT5 knockdown or inhibition could reverse this oncogenic splicing pattern and further created a gene‐based score for PRMT5 inhibition sensitivity [71].”
BackgroundStructure of the human activated spliceosome in three conformational states
Zhang, X., Yan, C., Zhan, X., Li, L., Lei, J., & Shi, Y. (2018) · Cell Research · doi:10.1038/cr.2018.14 · Cited by 206 · cited 1×
“complex made up of multiple small nuclear RNA (snRNAs)–U1, U2, U4, U5 and U6–that combine with over 80 proteins to create RNA‐protein complexes known as small nuclear ribonucleoproteins (snRNPs, pronounced “snurps”) [69,70].”
Backgroundvan Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., van de Ven, P. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2564-z · Cited by 202 · cited 1×
“However, while they work upfront, resistance is rapid and being able to better understand this resistance is necessary to develop second‐line therapeutics [88].”
BackgroundTapping the RNA world for therapeutics
Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 194 · cited 1×
“Many drugs have now been designed to specifically target SF3B1, including in glioma [76,77].”
BackgroundOliva, C. R., Nozell, S. E., Diers, A., McClugage, S. G., Sarkaria, J. N., Markert, J. M., Darley-Usmar, V. M., Bailey, S. M., Gillespie, G. Y., Landar, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147504 · Cited by 193
MIZUI, Y., SAKAI, T., IWATA, M., UENAKA, T., OKAMOTO, K., SHIMIZU, H., YAMORI, T., YOSHIMATSU, K., & ASADA, M. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.188 · Cited by 185 · cited 1×
“A third SF3B1‐targeting agent, palidomide B, has also been shown to be effective against multiple central nervous system (CNS) cancer lines, even before its target was fully realized [79].”
BackgroundSplicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B
Zhou, X., Wang, R., Li, X., Yu, L., Hua, D., Sun, C., Shi, C., Luo, W., Rao, C., Jiang, Z., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120279 · Cited by 179 · cited 1×
“This isoform was membrane‐ bound and promoted GBM cell proliferation, invasion, and survival [84].”
BackgroundMazor, G., Levin, L., Picard, D., Ahmadov, U., Carén, H., Borkhardt, A., Reifenberger, G., Leprivier, G., Remke, M., & Rotblat, B. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1477-5 · Cited by 174 · cited 1×
“ALDH1A1 has been used as a marker for TMZ-resistant GSCs, where inhibition of ALDH1A1 increased responsiveness to TMZ treatment [111].”
BackgroundPerrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180444 · Cited by 171 · cited 1×
“Though trials have been successful in some patients, no treatment strategy has significantly improved survival of recurrent GBM patients with an average overall survival of less than six months [31,32].”
BackgroundImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 166
Collingridge, D. R., Piepmeier, J. M., Rockwell, S., & Knisely, J. P. S. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00121-8 · Cited by 164 · cited 1×
“Normal brain oxygenation was shown to be ~40 mmHg by Eppendorf needle electrode, whereas GBM clocked in at ~10 mmHg where 0-10 mmHg was shown to correlate with RT resistance [114,115].”
MethodBabic, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.013 · Cited by 164 · cited 1×
“hnRNPA1 promotes the splicing of Delta Max, a Myc interacting protein, which augments EGFRvIII expression and promotes GBM cell proliferation in vitro [86].”
BackgroundIncreased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas
Engler, J. R., Robinson, A. E., Smirnov, I., Hodgson, J. G., Berger, M. S., Gupta, N., James, C. D., Molinaro, A., & Phillips, J. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043339 · Cited by 162 · cited 2×
“TAMs are the dominant infiltrating immune population in glioma constituting around 30–40% of the total tumor volume [25,132,138].”
BackgroundSherriff, J., Tamangani, J., Senthil, L., Cruickshank, G., Spooner, D. A., Jones, B., Brookes, C. L., & Sanghera, P. (2013) · British Journal of Radiology · doi:10.1259/bjr.20120414 · Cited by 162 · cited 1×
“In a study of 105 patients, who received RT‐TMZ treatment, central relapse occurred in 77% patients at the site of the original tumor edge, was the most predominant pattern of relapse [28].”
BackgroundRandomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Field, K. M., Simes, J., Nowak, A. K., Cher, L., Wheeler, H., Hovey, E. J., Brown, C. S. B., Barnes, E. H., Sawkins, K., Livingstone, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov104 · Cited by 160 · cited 1×
“Though trials have been successful in some patients, no treatment strategy has significantly improved survival of recurrent GBM patients with an average overall survival of less than six months [31,32].”
BackgroundEffects of hypoxia and HIFs on cancer metabolism
Mucaj, V., Shay, J. E. S., & Simon, M. C. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1070-5 · Cited by 159 · cited 1×
“HIF1α is able to work in conjunction with the oncogene c-Myc to alter tumor metabolism [119].”
BackgroundTemozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Daniel, P. M., Sabri, S., Chaddad, A., Meehan, B., Jean‐Claude, B. J., Rak, J. W., & Abdulkarim, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00041 · Cited by 155 · cited 1×
“Such analysis revealed recurrent tumor types of two genomic outcomes–hypermutant and non‐hypermutant [59].”
BackgroundKitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151 · cited 2×
“even MGMT hypermethylated glioma cells show robust expression of MGMT through promoter‐independent mechanisms, thereby developing resistance to TMZ treatment [7,8].”
BackgroundSchoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Hejleh, T. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.008 · Cited by 149
Mi, Y., Guo, N., Luan, J., Cheng, J., Hu, Z., Jiang, P., Jin, W., & Gao, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00737 · Cited by 149 · cited 1×
“However, the BBB is disrupted by inflammation, rapid expansion of GBM tumors, and tumor infiltration by immunosuppressive immune cells from blood circulation categorizing it as a ‘cold’ tumor [130].”
BackgroundHuang, J., Chaudhary, R. T., Cohen, A. L., Fink, K., Goldlust, S. A., Boockvar, J. A., Chinnaiyan, P., Wan, L., Marcus, S. G., & Campian, J. L. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03125-y · Cited by 142 · cited 1×
“Clinical trials are currently investigating the therapeutic potential of ALDH1A1 inhibitors in combination with TMZ and RT [112].”
BackgroundActivation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma
Sadahiro, H., Kang, K.-D., Gibson, J. T., Minata, M., Yu, H., Shi, J., Chhipa, R., Chen, Z., Lu, S., Simoni, Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2433 · Cited by 141 · cited 1×
“If successful, this approach might be promoted to clinical trials [47].”
BackgroundCryo-EM structure of a human activated spliceosome (early Bact) at 4.9 angstrom.
Zhang, X., Yan, C., Zhan, X., Li, L., Lei, J., & Shi, Y. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb5z58/pdb · Cited by 139
Hubert, C. G., Bradley, R. K., Ding, Y., Toledo, C. M., Herman, J., Skutt-Kakaria, K., Girard, E. J., Davison, J., Berndt, J., Corrin, P., et al. (2013) · Genes & Development · doi:10.1101/gad.212548.112 · Cited by 138 · cited 1×
“The SF3B1‐targeting compounds spliceostatin A and sudemycin C1 have been shown to specifically target glioma stem cells, which are notoriously known for being therapy re‐ sistant, over normal neural stem cells [78].”
BackgroundMudassar, F., Shen, H., O’Neill, G., & Hau, E. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01724-6 · Cited by 129 · cited 1×
“Importantly, atovaquone is able to cross the BBB, warranting more research into this potentially promising therapeutic avenue for drug resistant gliomas [129].”
BackgroundManagement of glioblastoma after recurrence: A changing paradigm
Mallick, S., Benson, R., Hakim, A., & Rath, G. K. (2016) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2016.07.001 · Cited by 123 · cited 2×
“In a study by Mallick et al., 2016, a treatment algorithm has been proposed for recurrent glioma patients based on disease state and patient profile [30].”
BackgroundThe Oxygen Effect in Radiation Inactivation of DNA and Enzymes
Quintiliani, M. (1986) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008614550981 · Cited by 119 · cited 1×
“Hypoxia, or physiologically low levels of oxygen tension in the tumor, is a major cause of radio‐resistance in glioma as RT induces DNA damage but does not maintain its effects [22].”
BackgroundChou, C.-W., Wang, C.-C., Wu, C., Lin, Y., Lee, Y.-C., Cheng, Y.-W., & Hsieh, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos195 · Cited by 118 · cited 1×
“Additionally, in GBM xenografts it has been shown that hypoxic stress increases hypoxia‐inducible factor 1 (HIF‐1)‐mediated induc‐ tion of the drug efflux transporter ABCB1, leading to chemo‐resistance [23].”
BackgroundInoue, D., Bradley, R. K., & Abdel-Wahab, O. I. (2016) · Genes & Development · doi:10.1101/gad.278424.116 · Cited by 118
Song, X., Wan, X., Huang, T., Zeng, C., Sastry, N. G., Wu, B., James, C. D., Horbinski, C., Nakano, I., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1504 · Cited by 109 · cited 1×
“Overexpression of SRSF3 in GBM patient samples and GSCs was shown to effect exon usage of multiple mitosis‐related genes, where knockout normalized exon usage and increased overall survival in mouse models [17].”
BackgroundSelf-citationNaeini, K. M., Pope, W. B., Cloughesy, T. F., Harris, R. J., Lai, A., Eskin, A., Chowdhury, R., Phillips, H. S., Nghiemphu, P. L., Behbahanian, Y., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not008 · Cited by 101
Correa, B. R., de Araujo, P. R., Qiao, M., Burns, S. C., Chen, C., Schlegel, R., Agarwal, S., Galante, P. A. F., & Penalva, L. O. F. (2016) · Genome Biology · doi:10.1186/s13059-016-0990-4 · Cited by 101 · cited 5×
“One of the larger studies evaluated over 1,500 RBPs, finding 223 and 225 overexpressed between GBM and normal brain and glioma stem cells (GSCs) and neural stem cells (NSCs), respectively, with 58 overlapping between GBM and GSCs [82].”
InfluentialLibby, C. J., Tran, A. N., Scott, S. E., Griguer, C. E., & Hjelmeland, A. B. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.01.004 · Cited by 99 · cited 1×
“when oxygen is present, which is less efficient in ATP production as compared to OXPHOS but can utilize glucose in other biosynthetic pathways for the production of li‐ pids, nucleic acids, and some proteins [15].”
BackgroundMolecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 93 · cited 1×
“Glioblastoma (GBM) is the most aggressive (WHO grade IV) form of glioma arising from astrocytes or their precursors in the Central Nervous System [1].”
BackgroundLieberman, F. S. (2017) · F1000Research · doi:10.12688/f1000research.11493.1 · Cited by 93 · cited 1×
“Despite multi‐ ple treatment approaches, tumors inevitably relapse after six to nine months of primary treatment and there is no standard treatment for recurrent GBM patients [27].”
BackgroundValtorta, S., Dico, A. L., Raccagni, I., Gaglio, D., Belloli, S., Politi, L. S., Martelli, C., Diceglie, C., Bonanomi, M., Ercoli, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23028 · Cited by 92
Current State and Future Prospects of Immunotherapy for Glioma
Kamran, N., Alghamri, M. S., Núñez, F. J., Shah, D., Asad, A. S., Candolfi, M., Altshuler, D. B., Lowenstein, P. R., & Castro, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0122 · Cited by 84
Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
Dico, A. L., Martelli, C., Diceglie, C., Lucignani, G., & Ottobrini, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00249 · Cited by 84
Tackling the Many Facets of Glioblastoma Heterogeneity
Tirosh, I., & Suvà, M. L. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.02.005 · Cited by 82 · cited 1×
“These organoid tumor models also recapitulate other features of GBM tumors which are difficult to model in in vitro conditions such as hypoxic gradients and tumor heterogeneity [57,58].”
BackgroundBernstock, J. D., Mooney, J. H., Ilyas, A., Chagoya, G., Estévez-Ordoñez, D., Ibrahim, A. G. A., & Nakano, I. (2019) · Journal of neurosurgery · doi:10.3171/2019.5.jns19364 · Cited by 80 · cited 1×
“RT, which has the strongest impact on proneural cells, and TMZ which showed efficacy in rapidly proliferating CL GBM cells, might be addressing the complex issue of tumor heterogeneity in GBM [48].”
BackgroundVisconte, V., Nakashima, M. O., & Rogers, H. J. (2019) · Cancers · doi:10.3390/cancers11121844 · Cited by 80
Warren, K. E., Gururangan, S., Geyer, J. R., McLendon, R. E., Poussaint, T. Y., Wallace, D., Balis, F. M., Berg, S. L., Packer, R. J., Goldman, S., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0709-z · Cited by 76 · cited 1×
“Nevertheless, combination therapy using an MGMT inhibitor, O6‐benzylguanine (O6BG) alongside TMZ did not show any clinical benefit compared to TMZ alone [9,10].”
BackgroundRelapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences
Tosoni, A., Franceschi, E., Poggi, R., & Brandes, A. A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0422-4 · Cited by 72 · cited 1×
“In MGMT‐methylated patients relapsing after TMZ treatment, a rechallenge could be proposed [29].”
BackgroundRescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients
Han, S. I., Ma, E., Wang, X., Yu, C., Dong, T., Zhan, W., Wei, X., Liang, G., & Feng, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.4944 · Cited by 70 · cited 4×
“The GBM TME is a diverse milieu of both neoplastic and non-neoplastic cells in which the tumor cells grow and develop diversity within the tumor.”
BackgroundInfluentialHypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma
Gérard, M., Corroyer‐Dulmont, A., Lesueur, P., Collet, S., Chérel, M., Bourgeois, M., Stefan, D., Limkin, E. J., Perrio, C., Guillamo, J., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00117 · Cited by 69
Tantillo, E., Vannini, E., Cerri, C., Spalletti, C., Colistra, A., Mazzanti, C. M., Costa, M., & Caleo, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104942 · Cited by 63
Mechanism of spliceosome remodeling by the ATPase/helicase Prp2 and its coactivator Spp2
Bai, R., Wan, R., Yan, C., Jia, Q., Lei, J., & Shi, Y. (2021) · Science · doi:10.1126/science.abe8863 · Cited by 59 · cited 1×
“AS is the process of removing introns and joining together exons [66] in ways that are dictated by the spliceo‐ some and many accompanying splicing factors [67,68].”
BackgroundEnvironmental stimuli shape microglial plasticity in glioma
Garofalo, S., Porzia, A., Mainiero, F., Di Angelantonio, S., Cortese, B., Basilico, B., Pagani, F., Cignitti, G., Chece, G., Maggio, R., et al. (2017) · eLife · doi:10.7554/elife.33415 · Cited by 58
RNA processing as an alternative route to attack glioblastoma
Meliso, F. M., Hubert, C. G., Galante, P. A. F., & Penalva, L. O. F. (2017) · Human Genetics · doi:10.1007/s00439-017-1819-2 · Cited by 57 · cited 1×
“As the brain is the most alternatively spliced organ, it will be interesting to see the advances made to better understand and target aberrant splicing pathways in GBM [154].”
BackgroundTiek, D. M., Rone, J. D., Graham, G. T., Pannkuk, E. L., Haddad, B. R., & Riggins, R. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-25588-1 · Cited by 56
Self-citationKoga, T., Chaim, I. A., Benitez, J. A., Markmiller, S., Parisian, A. D., Hevner, R. F., Turner, K. M., Hessenauer, F. M., D’Antonio, M., Nguyen, N.-P. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14312-1 · Cited by 55 · cited 1×
“In‐ troduction of GBM‐associated genetic driver mutations in hiPSCs (GBM avatars) has been shown to result in the formation of high‐grade gliomas that recapitulate the authentic can‐ cer pathobiology [56].”
BackgroundYu, Z., Zhao, G., LI, P., Li, Y., Zhou, G., Chen, Y., & Xie, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.4315 · Cited by 54
Guardia, G. D. A., Corrêa, B., Araujo, P. R. D., Qiao, M., Burns, S., Penalva, L. O. F., & Galante, P. A. F. (2020) · npj Genomic Medicine · doi:10.1038/s41525-019-0108-5 · Cited by 54 · cited 1×
“of cancer, contributing to PN‐MES transition and subsequent tumor heterogeneity and resistance [21].”
BackgroundGupta, K., Vučković, I., Zhang, S., Xiong, Y., Carlson, B. L., Jacobs, J., Olson, I., Petterson, X.-M. T., Macura, S. I., Sarkaria, J. N., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00535 · Cited by 44 · cited 3×
“glutathione (GSH), are decreased, with an increase of ATP and GTP [91].”
BackgroundMechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme
Fisher, T., Galanti, G., Lavie, G., Jacob‐Hirsch, J., Kventsel, I., Zeligson, S., Winkler, R. E., Simon, A. J., Amariglio, N., Rechavi, G., et al. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318157053f · Cited by 43
Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells
de Mey, S., Dufait, I., Jiang, H., Corbet, C., Wang, H., Gucht, M. V. D., Kerkhove, L., Ka, L. L., Vandenplas, H., Gevaert, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249367 · Cited by 37 · cited 1×
“This effect has been shown both in vitro and in vivo with concurrent radiation and in hypoxic conditions [100].”
BackgroundAnalysis of temozolomide resistance in low‐grade gliomas using a mechanistic mathematical model
Ollier, É., Mazzocco, P., Ricard, D., Kaloshi, G., Idbaïh, A., Alentorn, A., Psimaras, D., Honnorat, J., Delattre, J., Grenier, E., et al. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12259 · Cited by 36 · cited 1×
“into the acquired resistance category, suggesting that TMZ paradoxically increases tumor progression in a subset of patients and hence identification of such a risk group is of high importance [65].”
BackgroundTargeting tumour hypoxia: shifting focus from oxygen supply to demand
Coates, J. T. T., Skwarski, M., & Higgins, G. S. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170843 · Cited by 36
Spliceosome Mutations in Uveal Melanoma
Nguyen, J. Q. N., Drabarek, W., Yavuzyiğitoğlu, S., Salsench, E. M., Verdijk, R. M., Naus, N. C., de Klein, A., Kılıç, E., & Brosens, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249546 · Cited by 33
Castro, M. L., McConnell, M. J., & Herst, P. M. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.022 · Cited by 31 · cited 1×
“sitization of GBM to be a ROS‐dependent cell death [96].”
BackgroundRole of alternative splicing signatures in the prognosis of glioblastoma
Xie, Z., Wu, H., Dang, Y., & Chen, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2666 · Cited by 31
Temozolomide Treatment Increases Fatty Acid Uptake in Glioblastoma Stem Cells
Caragher, S. P., Miska, J. M., Shireman, J. M., Park, C. H., Muroski, M. E., Lesniak, M. S., & Ahmed, A. U. (2020) · Cancers · doi:10.3390/cancers12113126 · Cited by 30 · cited 1×
“Another potential metabolic target is fatty acid oxidation, as Caragher et al recently showed that TMZ induces a dependence on endogenous fatty acid oxidation, that was enriched in CD133+ GSCs and the proneural GBM subtype [110].”
BackgroundRNA processing genes characterize RNA splicing and further stratify lower-grade glioma
Chai, R., Li, Y., Zhang, K., Chang, Y., Liu, Y., Zhao, Z., Wang, Z., Chang, Y., Li, G., Wang, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130591 · Cited by 27
Tiek, D. M., Khatib, S. A., Trepicchio, C. J., Heckler, M. M., Divekar, S. D., Sarkaria, J. N., Glasgow, E. F., & Riggins, R. B. (2019) · The FASEB Journal · doi:10.1096/fj.201901075r · Cited by 24 · cited 1×
“Using both an inhibitor for SRSF6 phosphorylation, TG‐ 003, and an ERRb agonist, DY131, the isoform ratio was shifted to favor the ERRb2 iso‐ form, which could be activated by DY131 to promote cell death [85].”
MethodSelf-citationA SDHB malignant paraganglioma with dramatic response to temozolomide–capecitabine
Nozières, C., Walter, T., Joly, M., Giraud, S., Scoazec, J., Borson‐Chazot, F., Simon, C., Riou, J. P., & Lombard‐Bohas, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1098 · Cited by 22 · cited 1×
“Furthermore, in paraganglioma, an inactivating mutation in Complex II has been associated with increased TMZ responsiveness, underscoring the importance of the ETC in TMZ efficacy [106,107].”
BackgroundSteensma, D. P., Maris, M. B., Yang, J., Donnellan, W. B., Brunner, A. M., McMasters, M., Greenberg, P. L., Komrokji, R. S., Klimek, V. M., Goldberg, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps7075 · Cited by 16
Hypermutations in gliomas: a potential immunotherapy target.
Finocchiaro, G., Langella, T., Corbetta, C., & Pellegatta, S. (2017) · PubMed · Cited by 15
Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Newman, W. C., & Monaco, E. A. (2015) · Neurosurgery · doi:10.1227/01.neu.0000471838.05005.51 · Cited by 5
GENE-49. RNA PROCESSING GENES CHARACTERIZE RNA SPLICING AND FURTHER STRATIFY LOWER-GRADE GLIOMA
Chai, R., Jiang, T., & Wang, Y. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz175.451
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
BackgroundSelf-citationGlioma: molecular signature and crossroads with tumor microenvironment
Barthel, L., Hadamitzky, M., Dammann, P., Schedlowski, M., Sure, U., Thakur, B. K., & Hetze, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09997-9 · Cited by 211
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
White, J., White, M. P. J., Wickremesekera, A., Peng, L., & Gray, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05301-9 · Cited by 168
“5) [28, 128].”
BackgroundInfluentialCheng, G., Kwong, C. H. T., Wang, Q., Kam, H., Xie, B., Lee, S. M., Chen, G., & Wang, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c00041 · Cited by 157
Molecular Mechanisms of Drug Resistance in Glioblastoma
Dymova, M. A., Kuligina, E. V., & Richter, V. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126385 · Cited by 152
“If the BBB is disrupted by tumor proliferation or inflammation, then the tumor can be infiltrated by immunosuppressive immune cells [67].”
Background
Metadata
- Authors
- Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Cheng, Shi-Yuan
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-02-24
- Volume
- 10
- Issue
- 3
- Pages
- 484
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7995978
- OpenAlex
- W3132558808
- Cited by
- 169
- References
- 157
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 27 · 2023: 36 · 2022: 26 · 2021: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (CA221747, CA234799)
- National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
- The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, treatment resistance, tumor recurrence, tumor heterogeneity, hypermutation, cancer metabolomics, alternative splicing, hypoxia, tumor microenvironment, immunosuppression, immunotherapy resistance, tumor evolution
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.